Assessment of an optimized manufacturing process for inactivated quadrivalent influenza vaccine: a phase III, randomized, double-blind, safety and immunogenicity study in children and adults

BACKGROUND: GSK has modified the licensed monovalent bulk manufacturing process for its split-virion inactivated quadrivalent influenza vaccine (IIV4) to harmonize the process among different strains, resulting in an increased number of finished vaccine doses, while compensating for the change from...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:BMC Infect Dis
Main Authors: Claeys, Carine, Drame, Mamadou, García-Sicilia, José, Zaman, Khalequ, Carmona, Alfonso, Tran, Phu My, Miranda, Mariano, Martinón-Torres, Federico, Thollot, Franck, Horn, Michael, Schwarz, Tino F., Behre, Ulrich, Merino, José M., Sadowska-Krawczenko, Iwona, Szymański, Henryk, Schu, Peter, Neumeier, Elisabeth, Li, Ping, Jain, Varsha K., Innis, Bruce L.
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2018
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5907359/
https://ncbi.nlm.nih.gov/pubmed/29669531
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12879-018-3079-8
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados